Introduction
Endothelial cells (EC) play a dominant role in maintaining hemostatic balance within the vascular system. Smooth muscle cells (SMC) are the predominant cells within vasculature. An expanding area of research has been focused on the use of different gene delivery systems to alter various properties of EC, SMC and intact blood vessels. [1] [2] [3] [4] [5] [6] [7] [8] Murine leukemia retroviral vectors (MuLV) have been used to up-regulate long-term expression of a chosen therapeutic gene. 9 Disadvantages of this vector are instability, the requirement for dividing cells, and low efficiency gene transfer into human cells, especially in vivo. Some studies have attempted to increase the transduction efficiency to EC by using strategies such as multiple viral exposures 10 or increasing viral titers by ultracentrifugation 11 and were able to produce an average transduction efficiency of 15 to 57%.
The envelope G glycoprotein from the vesicular stomatitis virus (VSV-G) has been used to construct a pseudotyped MuLV with significant improvement in stability and transduction efficiency. 12, 13 The VSV-G pseudotyped MuLV can be concentrated to titers exceeding 10 9 colony formation units (c.f.u.)/ml through ultracentrifugation with minimal loss of infectivity.
14 Recently, stable packaging cell lines for production of VSV-G pseudotyped MuLV have been developed by applying a tetracyclinecontrolled expression system to minimize the VSV-Gassociated toxicity. [15] [16] [17] However, pseudotransduction (protein transfer) has been reported to be associated with the VSV-G pseudotyped MuLV. 18, 19 This pseudotyped vector has been successfully used to transfer genes into human peripheral blood lymphocytes, 19, 20 leukocytes, 21 and hepatocytes. 18 No previous report has shown its application on human vascular tissues.
In this study, we used the VSV-G pseudotyped MuLV retroviral vector (VSV-G/MuLV) carrying genes encoding for either ␤-galactosidase or human tissue-type plasminogen activator (tPA) to transduce human EC, SMC and saphenous vein (SV). tPA plays an important role in preventing thrombosis by cleaving plasminogen into plasmin, which will digest the fibrin in thrombus. Augmenting the tPA activity in EC may enhance the antithrombotic properties of the vessel. Our results show that the VSV-G pseudotyped MuLV retroviral vector has significantly higher transduction efficiency in vitro in human EC, SMC and SV than Ampho/MuLV. We also eliminated the possibility of pseudotransduction associated with the VSV-G pseudotyped MuLV by demonstrating that transduction achieved by the vector is true gene transfer instead of protein transfer.
Results

Transduction of EC and SMC with MuLV vectors
Two types of retroviral supernatants, VSV-G pseudotyped MuLV and Ampho/MuLV (Figure 1) , were used to transduce three different human EC lines and one SMC line. Transduction efficiency was found to be independent of the EC line ( Table 1) . The average transduction efficiency of Ampho/MuLV on the different EC lines was 19% (range, 12-24%) and was 17% on SMC, as measured by ␤-galactosidase activity. The transduction efficiency of the VSV-G pseudotyped MuLV vector was significantly higher at 90% (range, 86-97%) for the EC lines and 92% for SMC line.
The titer of VSV-G/MuLV (6 × 10 6 c.f.u./ml) used to transduce EC was 10-fold higher than that of the Ampho/MuLV used (6 × 10 5 c.f.u./ml). The multiplicity of infection (MOI) for VSV-G/MuLV transduction was 100, whereas the MOI for amphotropic MuLV transduction was 10. The higher transduction efficiency of VSVGMuLV could be due to its higher MOI. To address this question, we diluted the VSV-G pseudotyped viral supernatant 10-fold and transduced 6 × 10 4 cells that would give the same MOI (viz., 10) as that of Ampho/MuLV. The results showed the transduction efficiency of the human EC line ECV304 with diluted VSV-G/MuLV was only decreased to 79% from the original 97% (data not shown). Therefore, at the same MOI, the transduction efficiency of VSV-G/MuLV still remained about four-fold higher than that of Ampho/MuLV.
Saphenous vein transduction in vitro
Excreta human SV segments were cultured in a modified organ culture dish. Transduction of the vein patches with Ampho/MuLV and VSV-G/MuLV viral vectors bearing lacZ gene was conducted after the veins were cultured for 7 days. Gene transfer was found to be more concentrated at the edges of SV patches ( Figure 2) . Comparing VSV-G/MuLV transduced (n = 10) veins with Ampho/MuLV transduced samples (n = 6) by surface en face blue cell counting, VSV-G/MuLV vector resulted in five-and 12-fold (P Ͻ 0.001, Table 1) higher transduction efficiency at the edge and in the center, respectively. Transduction was seen at the surface layer on both luminal and abluminal surfaces of the veins (Figure 2b ) and no penetration into the deeper layer was observed.
Transfer of tPA gene VSV-G pseudotyped MuLV carrying LtSN vector (VSV-G/tPA) was used to transduce EC. Four days after transduction with VSV-G/tPA, the tPA production of ECV304 increased to 23.5 ng/ml, which was 20-fold higher than untransduced cells (1.2 ng/ml), and 12-fold higher than cells transduced with amphotropic MuLV carrying LtSN vector (Ampho/tPA) (2 ng/ml) (Figure 3a) . The corresponding tPA activity was 38-fold and 87-fold higher in the VSV-G/tPA transduced cells (10.4 IU/ml) compared with the Ampho/tPA transduced cells (0.3 IU/ml) and the untransduced cells (0.1 IU/ml), respectively ( Figure  3b ). The tPA production, 23.5 ng/ml for tPA antigen and 10.4 IU/ml for tPA activity, from the unselected cells transduced with VSV-G/tPA are comparable with that from the selected stable transduced cells, 54 ng/ml and 13 IU/ml, respectively.
Gene transfer versus protein transfer
As reported by other investigators, 18, 19 the VSV-G pseudotyped MuLV can cause pseudotransduction when using the ␤-galactosidase gene as a marker gene. We performed four experiments to evaluate the possibility of pseudotransduction: (1) cotransfection of viral vector with a nonviral vector carrying lacZ gene; (2) correlation of transduction and reverse transcriptase activity; (3) correlation of transduction and cell proliferation; and (4) stability of gene expression.
X-gal staining was performed 7 days after transduction (a). En face observation (× 40) of the vein patch showed more transduced cells at the edge (c) than at the center (d). The vein patch (a) was sectioned and Verhoeff's stained (b) showing transduction on both the luminal (L) and abluminal (A) surfaces and greater concentration of the transduced cells (blue cells) at the edge (E) than the center (C) (× 40).
In the first experiment, a nonviral vector plasmid pCMV␤ was cotransfected with the other three plasmids (LtSN, HIT60, CVG) required for production of functional viral particles ( Figure 1 ). The producer cells should have ␤-galactosidase expressed from pCMV␤, whereas the viral vector produced from the cotransfection would have LtSN but without the lacZ gene. When this vector is used to transduce cells, the recipient cells should not show ␤-galactosidase activity. If there were protein transfer via the virus, the recipient cells would demonstrate ␤-galactosidase activity following transduction. Our results showed that while the producer cells stained positive for the ␤-galactosidase activity ( Figure 4A ), the recipient NIH 3T3 cells did not stained positive by X-gal ( Figure  4B ) after transduction with the viral vector generated from producer cells cotransfected with the four plasmids. These results indicate that there was no protein transfer through the VSV-G pseudotyped viral vector. Similar results were obtained using EC as the recipient cells (data not shown). In addition to the presence of ␤-galactosidase protein, we also examined for green fluorescence protein (GFP) transfer through the virus. In this case, the viral supernatant was generated by cotransfecting nonviral expression plasmid pGFP into 293T/17 cells along with three other plasmids: pCnBgSN, HIT60, CVG (Figure 1) . The virus could not transfer the GFP from the producer cells into the recipient cells although there was high expression of GFP inside the producer cells (data not shown). 
Transduction requires reverse transcription
Retrovirus-mediated gene transfer requires reverse transcription of RNA into DNA followed by integration of the DNA into the chromosome. We used a reverse transcriptase inhibitor (AZT) to block the reverse transcription to study the pseudotransduction. When transduction of the cells was carried out with VSV-G/MuLV vector in the presence of AZT there was no ␤-galactosidase activity detected in the transduced cells (data not shown), indicating that the inhibition of reverse transcription does eliminate transduction. This demonstrates that VSV-G pseudotyped MuLV mediates true gene transfer.
Transduction requires cell proliferation
Gene transfer using the MuLV vector requires cells to be dividing, 22 while protein transfer is independent of cell proliferation. To eliminate further the possibility of protein transfer, the ECV cells were ␥-irradiated to arrest cell proliferation. After the cells were exposed to different doses of radiation, the cells were transduced with VSV-G/MuLV and the transduction efficiencies were analyzed (Figure 5a ). The results showed the transduction efficiency of VSV-G/MuLV decreased as the radiation dosage increased. When the dosage was high enough (20 Gy) to arrest proliferation of the majority of cells, no cells were transduced by VSV-G/MuLV. Furthermore, the vein transduction experiment also shows that more cell growth in the edge of the specimen correlates with more transduction there. These data indicate that transduction by VSV-G/MuLV requires cell proliferation, which further supports the observed transduction to be true gene transfer rather than pseudotransduction.
Stability of gene expression
Another method used to distinguish pseudotransduction from real gene transfer was to examine the stability of transferred gene expression. If viral particles could transfer proteins from producer cells into recipient cells, the amount of transferred protein would be limited, and its activity transient. Thus, after several passages, the population of cells retaining the transferred protein would decrease. On the other hand, the expression of the protein resulting from the transferred gene would be stable and the population of the cells possessing the gene would not decrease with passage. Based on this theory, we designed an experiment to study the stability of gene expression. ECV304 cells were transduced with either VSV-G/MuLV or Ampho/MuLV carrying the lacZ gene. Without selection, the transduced cells were passed nine times within 30 days. After each passage, the cells were analyzed for their ␤-galactosidase activity. No decrease in the percentage of cells having positive ␤-galactosidase activity was observed following nine passages after transduction (Figure 5b ). The percentage of VSV-G/MuLV transduced cells with positive ␤-galactosidase activity was 85%, while only 13% of Ampho/MuLV transduced cells had the ␤-galactosidase activity.
Furthermore, the increased tPA production as a function of time from VSV-G/tPA transduced EC (Figure 3 ) indicated that the increased tPA concentration resulted from protein synthesis inside the transduced cells, instead of protein transfer through the vector. 11 reported 15% and 40% transduction efficiency in EC and SMC respectively, by concentrating viral titers to an MOI of 1150 by centrifugation. Transduction efficiency of the VSV-G pseudotyped vector is considerably higher even with simpler strategies such as single viral exposure and at a lower MOI of around 100. Similarly, the cultured vein patch can also be efficiently transduced in vitro with VSV-G/MuLV ( Table 1 ). The VSV-G pseudotyped MuLV vector has been reported to be an efficient gene transfer agent for use in a variety of human cell types. [19] [20] [21] 23 However, pseudotransduction associated with the VSV-G pseudotyped vector has also been reported. 18, 19 Furthermore, gene transfer in hepatocytes with the VSV-G pseudotyped vector was reported to be about 10-fold less efficient than amphotropic vector at the same MOI. 18 In our study, we have demonstrated via four different experiments that there was no protein transfer via viral particles. In the cotransfection of four plasmid experiments, the proteins (either ␤-Gal or GFP) expressed in the producer cells could not be transferred to recipient cells via viral particles (Figure 4 ). This demonstrated that no protein transfer occurred via the viral vector. In addition, when we blocked the activity of reverse transcriptase during transduction, the cells did not express ␤-Gal protein, thereby indicating that the transduction is a result of reverse transcription from RNA into DNA followed by integration into the chromosome. The correlation of transduction efficiency and cell proliferation (Figure 5a ) further supports the conclusion that no protein transfer occurs with the VSV-G pseudotyped vector. Finally, gene expression was stable (Figure 5b ), indicating that the enzyme detected in the transduced cells truly arose from gene expression.
One difference between our study and previous studies 18, 19 was the processing of the viral supernatant. The viral supernatant used in our study was directly collected from cotransfection without concentration whereas Kay's and Sadelain's groups concentrated the viral supernatant via ultracentrifugation. Perhaps ultracentrifugation altered the pseudotyped vector leading to pseudotransduction in their experiments. It is also possible that the pseudotransduction phenomenon is cell type specific.
This high transduction efficiency could be a result of several factors. First, the VSV-G glycoprotein is a single chain peptide that has been found to be more stable than the MuLV envelope. The stability of the envelope results in higher titers of viral supernatant that contributes in part to its high transduction efficiency. At 10 times higher MOI, the transduction efficiency of the pseudotyped vector was five-to six-times higher than that of the amphotropic MuLV whereas at the same MOI, the transduction efficiency still remained about four-fold higher. Hence, it is likely that only 20% of the enhanced transduction that we noticed was contributed by the increased viral concentration, with the remaining 80% being a direct consequence of the better transduction efficiency of the pseudotyped vector. Second, the number of receptors available for virus binding corresponds to the transduction efficiency. Although the VSV-G receptor has not been definitively identified, evidence suggests that the receptor might be a ubiquitous membrane glycolipid, Some previous reports have suggested impaired proliferative capacity and phenotypic changes of endothelial cells associated with retroviral gene transfer. The primary aim of our study was to describe better transduction efficiency with the use of this vector and hence, we did not analyze in detail the markers of phenotypic alterations. However, neither did we notice any obvious morphological changes in transduced EC nor have we seen poor adhesion of EC seeded on to PTFE and Dacron graft surfaces (data presented elsewhere). Furthermore, proliferation of vascular cells transduced with this pseudotyped vector was no different from that of control cells (data not shown). This could be a result of, among other things, the use of human vascular cells and tissues and lack of selection in our protocol, both of which have been suggested to play a role in phenotypic changes. 10 Since vascular EC in the human body are quiescent with a slow turnover, the application of the VSV-G pseudotyped vector to in vivo gene transfer may be limited because it can only transduce the proliferating cells; however, it will still be a useful vector for in vivo gene transfer, and for ex vivo manipulation of vascular cells. For in vivo application, vascular cells will proliferate faster when the vessel is injured (eg by balloon injury or endarterectomy). In a rat carotid injury model of vascular restenosis, VSV-G pseudotyped retroviral vectors have shown enhanced transduction of neointimal cells in vivo (collaboration with Dr FL Hall, University of Southern California). For ex vivo application, the in vitro genetically engineered EC and SMC can be seeded on to prosthetic vascular grafts. The grafts seeded with EC secreting high levels of tPA may be rendered thromboresistant, resulting in improved patency. Transduction of the cultured vein patch in vitro provides a model to study the neointima formation and its inhibition by transferring therapeutic (eg p53, NOS) genes.
Using this highly efficient VSV-G pseudotyped vector carrying the tPA gene to transduce EC, we found that immediately after transduction, without selection, the tPA concentration in the culture supernatant could reach similar levels as that measured from the selected stably transduced cells (Figure 3 ). These data indicate that by using the VSV-G pseudotyped vector, we can omit the step of selection of the transduced cells because most cells will be transduced with the vector. This can significantly reduce the amount of time required for the application of gene therapy.
Materials and methods
Cell culture ECV304 (CRL1998) and 293T/17 (CRL11268) 27 were obtained from America Type Culture Collection (Rockville, MD, USA). Both cell lines were maintained in Dulbecco's modified Eagle's medium (DMEM) (Gibco BRL, Gaithersburg, MD, USA) supplemented with 10% fetal bovine serum (FBS) (HyClone, Logan, UT, USA) and 2 mm glutamine (Gibco BRL). Human umbilical vein endothelial cells (HUVEC) were purchased from Clonetics (San Diego, CA, USA). HUVEC were cultured in an optimized EC medium: MCDB 131 medium (Gibco BRL), 20% FBS, 50 g/ml porcine intestinal mucosa-derived heparin (Sigma, St Louis, MO, USA), 50 g/ml EC growth supplement (Becton Dickinson, Franklin Lakes, NJ, USA), 2 mm l-glutamine, 50 units/ml penicillin, 50 g/ml streptomycin, 2.5 g/ml gentamicin and 2.5 g/ml amphotericin B. All cells were maintained in a humidified 37°C incubator with 5% CO 2 .
Isolation of EC and SMC Human saphenous vein endothelial cells (HSVEC) and SMC were isolated as described previously 28 from excreta human saphenous veins obtained from patients undergoing bypass surgery at the University of Southern California Hospitals. The protocol for using excreta human vein was approved by the Institutional Review Board (IRB No. 969-042). Briefly, the luminal surface of the vein was incubated with 0.1% collagenase I (Gibco BRL) for 10 min at 37°C. The dissociated EC were pelleted by centrifugation, resuspended with the EC media and plated on to 0.1% fibronectin pre-coated dishes.
Following EC dissociation, the remainder of the vein was used for SMC harvesting. The vein was incised longitudinally and the intimal layer was scraped off with a scalpel. These tissues were agitated in Dulbecco's phosphate-buffered saline (DPBS) containing collagenase I (1.8 mg/ml) and elastase (0.2 mg/ml) for 1 h at 37°C. The dissociated cells were pelleted by centrifugation and cultured in Williams' medium (Gibco BRL) containing 20% FBS, l-glutamine (2 mm), and the antibiotics mentioned above.
Confirmation of EC and SMC identity of each culture was performed. EC was characterized by cellular morphological observation under phase contrast microscopy, as well as fluorescent staining for acetylated low-density lipoprotein (Ac-LDL) uptake with Dil-Ac-LDL 29 (Biomedical Tech, Stoughton, MA, USA). SMC was identified by positive immunostaining to smooth muscle ␣-actin. Both EC and SMC were passed at a 1:5 ratio and used for experiments between passages two and 10.
Plasmids
The vector G1nBgSvNa (obtained from Genetic Therapy, Novartis, Gaithersburg, MD, USA) contains a lacZ gene encoding nuclear-localized ␤-galactosidase and a neomycin resistance gene (neo r ) encoding for neomycin phosphotransferase. The expression of lacZ is driven by the MuLV promoter, while the neo r is controlled by a Simian virus 40 (SV40) promoter. Plasmid pCnBgSN 30 is a retroviral vector generated by inserting the KpnI fragment of the vector G1nBgSvNa into pRV109 31 with a hybrid 5Ј cytomegalovirus (CMV) long terminal repeat (LTR) promoter which controls the expression of the lacZ gene (Figure 1) . Plasmid pHIT60 is a MoMuLV Gag and Pol expressing plasmid, whose expression is driven by a CMV promoter. 31 Plasmid pCVG is a CMV-driven VSV-G expression vector, generated by replacing the EcoRI fragment of the pCEE+ (a MoMuLV envelope protein expression vector) 32 with the EcoRI fragment of pHCMV-G, 33 a gift from Theodore Friedman, UC San Diego, containing the cDNA encoding for VSV-G. Plasmid pCAE is a CMV-driven plasmid expressing the amphotropic envelope from 4070A. 34 pCMV␤ (Clontech, Palo Alto, CA, USA) is a mammalian reporter vector expressing ␤-galactosidase from the CMV promoter. The retroviral vector plasmid pLtSN carrying tPA 3 was generously provided by Dr David Dichek, UC San Francisco.
Retroviral production and titer determination
Both amphotropic (Ampho/MuLV) and VSV-G pseudotyped MuLV (VSV-G/MuLV) vectors bearing a ␤-galactosidase reporter gene were generated from a transient three-plasmid transfection system 31 as described previously. 28 Briefly, 293T/17 cells were transfected by calcium phosphate precipitation with plasmids pCnBgSN, pHIT60, and pCVG for VSV-G/MuLV or pCAE for Ampho/MuLV (Figure 1) . The viral supernatants were harvested after sodium butyrate treatment, and the viral infectious titers were analyzed with both G418-resistant colony formation and ␤-galactosidase activity assay. The viral titers analyzed by both methods were found to be similar. The titers of VSV-G/MuLV and Ampho/MuLV were 6 × 10 6 and 6 × 10 5 c.f.u./ml, respectively. Viral vector produced from the system is replicationincompetent. The possibility of replication competent retrovirus generated from the system was eliminated by assays for reverse transcriptase activity. After eight passages of the transduced cells, the supernatants from the cell culture were analyzed for their reverse transcriptase activity and found to be negative. When the supernatants from these cultures were used to transduce fresh 3T3 cell lines, no transduction was found as assayed by ␤-galactosidase activity.
VSV-G pseudotyped MuLV carrying LtSN vector (VSV-G/tPA) was generated by transient transfection of 293T cells with plasmids pCVG, pHIT60 and pLtSN in the same way as the generation of CnBgSN vector mentioned above. The titer of both Ampho/MuLV/tPA and VSV-G/tPA was 2 × 10 5 c.f.u./ml.
Transduction of EC and SMC
The transduction efficiency assay was performed as follows: EC (5 × 10 4 cells) in 30-mm diameter wells of a sixwell plate were mixed with 0.5 ml of specified viral supernatants containing 8 g/ml polybrene at 37°C for 2 h, followed by the addition of 2 ml of fresh medium. The cells were analyzed for ␤-galactosidase expression following the titering procedure described above. Transduction efficiency was calculated by the ratio of blue cells (transduced) to the total cells contained in 10 randomly picked high power fields (200 ×).
Transduction of EC with LtSN viral vectors was accomplished by mixing the cells in six-well plates (3 × 10 4 cells per well plated a day before transduction) with 0.5 ml viral supernatants for 2 h followed by the addition of 1.5 ml fresh medium. After the specified posttransduction day, the cells were washed once with PBS and the culture medium was replaced with 2 ml of serum-free EC medium. The cells were then cultured at 37°C for 24 h and the supernatants were collected and stored at −70°C until used for tPA analysis (described below).
Transduction of SV
The transduction of human saphenous veins was previously described. 28 Briefly, rectangular (5 × 10 mm) vein patches were pinned down with two 25-gauge needles, luminal surface facing upwards, in a 60 × 20 mm Petri dish having a 6 mm layer of Sylgard 184 resin cured (Dow Corning, Midland, MI, USA) in its base. Vein segments were cultured with Williams' medium supplemented with 2 g/l sodium bicarbonate (Gibco/BRL), antibiotics as mentioned in Cell culture, 2 mm l-glutamine, and 30% (v/v) FBS. The culture medium was replaced every 2 days. Seven days after explantation, the vein was mixed with 1 ml of Ampho/MuLV or VSVG/MuLV viral supernatants containing 8 g/ml polybrene and cultured at 37°C for 2 h, followed by the addition of 3 ml of fresh medium. One member of each pair of vein patches was exposed to the Ampho/MuLV supernatant, whereas the other was exposed to the VSVG/MuLV supernatant. The veins were cultured for 7 more days and then fixed and stained for ␤-galactosidase expression. En face analysis of the luminal surface of vein segments was done under a microscope at 200 × magnification. The number of transduced cells per high power field (cells/h.p.f.) was counted from seven selected areas.
Determination of tPA concentration
The tPA fibrinolytic enzyme activity of the cell culture supernatant was determined by a chromogenic assay using the Chromolize tPA assay kit from Biopool (Ventura, CA, USA). The concentration of tPA in the supernatant was determined by measuring the tPA antigen concentration with an ELISA assay kit (TintElize tPA) from Biolpool.
Inhibition of reverse transcriptase NIH 3T3 cells (5 × 10 4 cells per well) were plated on sixwell plates the day before transduction. VSV-G/CnBgSN viral supernatant containing 1 m 3Ј-azido-2Ј, 3Ј-dideoxythymidine (AZT) (Sigma) was added to the wells. After 2 h of incubation, the supernatants were replaced with fresh medium containing AZT. Two days later, the cells were fixed and analyzed for transduction efficiency by X-gal staining described above.
Radiation of cells ECV304 were plated on 60 mm plates (8 × 10 4 cells/ml) and cultured overnight. The cells on the plates were irradiated at room temperature for 1 to 30 min with ␥-ray from 137 Cs at a dose rate of 1 Gy/min. The medium was removed after irradiation, and the cells were mixed with VSV-G/CnBgSN viral supernatant containing 8 g/ml polybrene. Following a 2-h incubation, the cells were cultured for 2 more days and then analyzed for transduction efficiency.
